The molecular pathogenesis of morphoea: from genetics to future treatment targets

Running title: The molecular pathogenesis of morphoea

Authors:
A.M. Saracino[1,2], C.P Denton[2,3], C.H. Orteu[1]

Institutions:
1. The Royal Free London NHS Foundation Trust
Department of Dermatology
2. University College London
Department of Rheumatology and Connective Tissue Diseases
Division of Medicine
3. The Royal Free London NHS Foundation Trust
Department of Rheumatology

Corresponding author:
Name -   Dr Amanda Saracino
Address -   Department of Dermatology
               The Royal Free Hospital
               Pond Street
               London
               NW3 2QG
Email -   a.saracino@nhs.net
Phone -   +44 (0)20 7830 2376

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?
- Morphoea has a number of distinct clinical subsets with variable anatomical distribution, morphology and depth of tissue involvement

- Susceptibility mechanisms (including genetics and underlying autoimmunity) and environmental triggers are at play in morphoea pathogenesis
- A variety of innate and adaptive inflammatory and profibrotic immunopathogenic mechanisms and signalling pathways have demonstrated roles in the pathogenesis of sclerotic skin disease

WHAT DOES THIS STUDY ADD?
- This review draws together what is currently known in the pathogenesis of systemic sclerosis and other fibrotic processes, to expand on and provide links with our current limited understanding of morphoea pathogenesis.
- We propose the key-inciting role of epidermal keratinocytes in morphoea pathogenesis based on the Blaschkoid nature of linear morphoea, and recognised role of keratinocyte derived factors and epidermal-dermal signalling pathways in the pathogenesis of sclerotic skin disease.
- We review underlying genetic and immunopathological mechanisms in morphoea, and suggest how these may link to recognised reproducible clinical subsets.
- Finally, we look ahead at possible future targeted and individualised therapeutic approaches in sclerotic skin disease and morphoea.

ABSTRACT

A number of immunoinflammatory and profibrotic mechanisms are recognised in the pathogenesis of broad sclerotic skin processes, and more specifically, morphoea. However, precise aetiopathogenesis is complex and remains unclear.

Morphoea is clinically heterogeneous, with variable anatomical patterning, depth of tissue involvement, and sclerotic, inflammatory, atrophic and dyspigmented morphology. Underlying mechanisms determining these reproducible clinical subsets are poorly understood, but of great clinical and therapeutic relevance. Regional susceptibility mechanisms (such as environmental triggers, mosaicism and positional identity) together with distinct pathogenic determinants (including innate, adaptive and imbalanced pro and anti-fibrotic signaling pathways) are likely implicated. In the age of genetic profiling and personalised medicine, improved characterisation of the environmental, systemic, local, genetic and immunopathologic factors underpinning morphoea pathogenesis, may open the door to novel targeted therapeutic approaches.

INTRODUCTION

A review of morphoea pathogenesis is timely with improved understanding of underlying molecular mechanisms likely to bring the advent of more targeted therapeutic approaches. However the clinical heterogeneity of morphoea, with variable anatomical patterning, morphology and depth of tissue involvement observed both within and between individuals, poses many clinical and pathogenic challenges (see Figure 1). Whilst key aetiologic, immunoinflammatory and profibrotic molecular mechanisms are likely shared across these subsets of morphoea, there must be underlying determinants of clinical heterogeneity.

Unmasking the genetic and molecular basis of this reproducibly observed clinical variability in morphoea has great therapeutic potential.

SUSCEPTIBILITY MECHANISMS

Systemic and regional genetic and epigenetic susceptibility mechanisms are all potentially at play in morphoea (see Figure 1 and 2). Certain HLA subtypes, including HLA-DRB1*04:04 and HLA-B*37, infer increased susceptibility, especially in generalized and linear subtypes[1], and morphoea is reported in first or second-degree relatives in 2% of cases[2 3 4].

A personal or family history of autoimmune or rheumatologic diseases is seen in up to 46% of those with morphoea[2 5 6.2 5 7-9]; sometimes more frequently in generalized or linear subtypes[2 7]. Hence, one may speculate that a shared susceptibility locus exists for these disorders. As such, the systemic autoimmune nature of morphoea is further recognised by a variety of autoantibodies[2 7 10 11]; antinuclear antibodies (ANA) can occur in 18 to 68%[2 9 12-20] and notably, more of those with ANA positivity appear to have extracutaneous manifestations[11].

Distinct genetic 'intrinsic subsets' in systemic sclerosis (SSc) have been described, with reproducible and temporally stable gene expression profiles correlating to inflammatory and fibroproliferative signatures, and related clinical heterogeneity[21-25]. Significantly, differences in gene expression can be mapped not only to fibroblasts, but also to epithelial, endothelial, smooth muscle, T and B cells[24 26]. Genome wide expression profiling of skin biopsies from three morphoea patients linked them to the inflammatory signature[23], hence implicating mediators such as interferon (IFN), interleukin (IL)-13, chemokine (C-C motif) ligand (CCL)-2, early growth response (EGR)-1 gene and others in pathogenesis[21-25]. Indeed, IFN-γ-inducible protein 10 (IP10, CXCL10) is elevated in children with morphoea[27] and acts via CXC-chemokine-receptor (CXCR)-3 to attract inflammatory cells to the skin.

Of great potential relevance to regional genetic susceptibility is evidence that linear morphoea follows Blaschko's lines of epidermal development; suggesting likely mosaicism for a mutation that causes increased susceptibility to morphoea at certain sites[28-39] (see Figure 1 and 2). However, that a fibroblast driven dermal process can be Blaschkoid raises many unanswered questions, but its feasibility is perhaps substantiated by the existence of other similar conditions, including focal dermal hypoplasia (FDH; Goltz syndrome)[40] and a recent report of Blaschkoid granuloma annulare[41]. This may highlight the potential role of epidermally-derived signalling and immunoinflammatory pathways in morphoea pathogenesis.

Finally, epigenetic mechanisms may provide a potential link between genetic susceptibility, environmental aetiology and site specificity (see Figure 1). Altered patterns of histone acetylation and DNA-methylation at multiple genetic loci have been demonstrated in SSc. This has included transcriptional silencing of repressive genes in SSc fibroblasts, resulting in increased profibrotic gene expression and transforming growth factor (TGF)-β induced responses[42 43]. The importance of microRNAs (miRNAs) in the pathogenesis of skin fibrosis is also emerging. Twenty-six miRNAs are shown to be deregulated in SSc skin and isolated fibroblasts, some forming part of a positive feedback profibrotic mechanism activated by TGF-β[44]. miR-21 and miR-155 are profibrotic and show elevated expression in SSc skin[45]. These miRNAs are in turn regulated by TGF-β and hence have, as their predicted targets, genes involved in matrix repair and remodelling; such as collagens, matrix

metallopeptidases (MMPs) and integrins[46]. Conversely, miR-30b levels are inversely correlated to modified Rodnan skin scores (mRSS) and appear to be related to increased platelet-derived growth factor (PDGFR) expression on dermal fibroblasts[47]. Notably, down-regulation of anti-fibrotic miR-7[48 49] and miR-196a50[50] have been demonstrated in the skin and serum of patients with morphoea, potentially contributing to overproduction of collagen type I.

TRIGGERING EVENTS

An array of environmental triggers are widely reported in the aetiology of morphoea, seemingly linking susceptibility mechanisms and eventual, but not inevitable, disease onset[51-53] (see Figure 1 and 2). Trauma, in the form of insect bites, injection/vaccination, repeated friction, surgery, penetrating trauma, radiotherapy and extreme exercise, may trigger morphoea in up to 16% of adults[54] and 9% of children[5]. Trauma related morphoea may occur at the affected site, or a more systemic response may be triggered, with site unrelated skin sclerosis also seen. Of relevance is isomorphic disseminated plaque morphoea, which occurs symmetrically and at sites of repeated minor friction induced trauma along the waistline, bra strap and inguinal creases[54 55] (see Figure 1). The mechanisms of trauma related morphoea remain somewhat elusive; enhanced innate signalling via toll-like receptor (TLR)-ligands inducing fibroblast activation and an abnormal wound healing response has been proposed[56]. Several vaccinations are implicated temporally and anatomically with morphoea, including hepatitis B, tetanus, vitamin B12 and more[57-64]. Whether this is purely trauma related (due to vessel injury, tissue hypoxia and subsequent immune activation) or potentially due to common adjuvant vaccine constituents, remains uncertain[65]. Somewhat similarly, post-irradiation morphoea predominantly occurs at the site of radiation and within 12 months of completing treatment (most commonly in the setting of breast cancer)[66 67]. However up to one-quarter of cases may extend beyond the radiation field and the immunopathology of this is not clear[66 67], but increased IL-4, IL-5 and TGF-β is suggested[68]. Infection also triggers morphoea[5] and perhaps most controversially, Borellia species are associated in some studies[69-75]. Finally, various drugs can seemingly initiate the development of skin sclerosis[76-80], and drug cessation does not necessarily result in resolution[79 81]. Specific drug related lymphocyte responses and autoantibody production, with consequent vascular damage, reactive oxygen species, IL-1, tumour necrosis factor (TNF)-α and TGF-β production may be involved[76 82].

PATHOGENESIS

A plausible model of morphoea pathogenesis would involve a triggering event in a susceptible individual that results in a cascade of innate and adaptive immunoinflammatory and profibrotic responses, involving potential epidermal signalling and mesenchymal drivers (see Figure 2). Notwithstanding morphologic variation and distinct patterning observed in different morphoea subsets, many of these fundamental immunopathogenic mechanisms are likely to be shared.

The epidermis
Keratinocytes
A number of factors known to be involved in dermal fibrosis can be produced by keratinocytes, including TGF-β, IL-1, IL-6, TNF-α, PDGF, fibroblast growth factor (FGF), CCL2, endothelin (ET)-1, fibrillin-1, friend leukaemia integrated transcription factor (Fli)-1, S100A9,

alpha-melanocyte-stimulating hormone (α-MSH) and others[83] (see Figure 2). Accordingly, fibroblasts are more contractile when cultured with epithelial cells[84] and keratinocytes can alter the expression of extracellular matrix (ECM) gene modulators such as connective tissue growth factor (CTGF), fibronectin and type 1 collagen[85 86] in experimental models. Furthermore, although little is documented in morphoea specifically, in the context of SSc skin, activated highly proliferative keratinocytes have been demonstrated in the epidermis[23] [87 88] and importantly, unstimulated keratinocytes promote myofibroblast activation independent of TGF-β[89].

S100A9 is induced in keratinocytes during epidermal stress and, via TLR4, stimulates fibroblast proliferation and over expression of CTGF by SSc fibroblasts[88 90]. Over expression of TLR-4 occurs in fibrosis and its profibrotic effects are related to potentiating TGF-β activity and suppression of antifibrotic miRNAs (eg. miR-29)[46]. CTGF mRNA and protein have been identified in dermal fibroblasts in morphoea[91 92]. Keratinocyte FGF-receptor 1 and 2 are also linked to S100A9 activity and fibrosis. FGF-receptor knockout mice demonstrate loss of claudins and occludin which causes transepidermal water loss, severe xerosis and resultant activation of γδ-T-cells and keratinocytes to produce IL-1, S100A8 and S100A9, promoting a profibrotic response[90].

α-MSH mediates melanocyte pigment production via melanocortin-1 receptors (MC1R), is up regulated in the epidermis and fibroblasts of human burn wounds and hypertrophic scars[93], and modulates pro and anti-inflammatory cytokines produced by keratinocytes, monocytes and fibroblasts[94]. Conversely, and signifying its physiological homeostatic role, α-MSH (via MC1R) antagonizes cutaneous fibrosis induced by repeated TGF-β exposure and bleomycin[95-97]. As such, MC1R knockout mice have demonstrated a susceptibility to fibrosis[98].

Fibrillin-1 is a major component of the microfibrillar ECM network. Its expression has been associated with diffuse cutaneous SSc of the 'fibroproliferative' signature[23] and antibodies against fibrillin-1 have been documented in patients with morphoea and SSc[99]. Stiff skin syndrome is due to mutations in the domain of fibrillin-1 that mediates integrin binding, and is characterized by sclerotic skin usually over the entire body; somewhat reminiscent of pansclerotic morphoea[100 101]. Further evidence connecting fibrillin-1 to sclerotic skin disease is the suggested link between variation at the fibrillin-1 gene locus and SSc in Choctaw Indians[102].

Finally, keratinocyte derived transcription factor Fli-1 has a demonstrated role in dermal fibrosis mouse models and SSc. Down-regulation of Fli-1 induces an SSc-like phenotype in fibroblasts, vascular endothelium and macrophages. Additionally, keratinocyte Fli-1 knockout mice exhibit enhanced skin fibrosis with increased IL-1, IL-6 and IL-8 expression[103].

Epidermal-dermal signaling and developmental pathways
Epidermal-dermal morphogenic signaling pathways (including Wingless and int homolog (Wnt), Sonic hedgehog (Shh) and Jagged-Notch) involved in embryonic development, tissue patterning, morphogenesis and wound repair, are of increasing interest in skin fibrosis[90 104-108] (see Figure 2). These pathways have been implicated in SSc[109-113] and are also of

potential relevance to patterning and morphologic variation seen clinically in morphoea; although little is confirmed in the present literature in this regard.

Jagged-Notch pathways, which control formation of boundaries between groups of cells during embryogenesis and mediate epithelial-mesenchymal transition, are over activated in fibroblasts in SSc[46][114]. Similarly, Shh is elevated in fibroblasts, endothelial cells and keratinocytes of SSc patients, allowing degradation of Gli proteins, thus promoting fibrosis[46][111][115].

Finally, and perhaps especially significant, is Wnt signaling, which originates in the epidermis. Normal stimulation of fibroblasts with Wnt ligands results in β-catenin-mediated expression of collagen, other matrix proteins, CTGF, enhanced fibroblast proliferation, myofibroblast differentiation and increased cell migration[116-120]. Genome expression profiling has demonstrated elevated expression of several Wnt ligands, receptors and decreased expression of Wnt antagonists in SSc[115][116][118-127]. Of further relevance to skin sclerosis, Wnt-β-catenin signaling and TGF-β pathways are known to interact, and peroxisome proliferator-activated receptor (PPAR)-γ (a recognized antifibrotic receptor which inhibits Wnt-β-catenin signaling) is decreased in SSc, thus promoting fibrosis[120]. Additionally, Wnt signaling inhibits epidermal responsiveness to FGF-receptors, providing another link between potentially important epidermal inciting pathways and dermal fibrosis. Finally, β-catenin independent keratinocyte derived Wnt5a is highly expressed in SSc fibroblasts, and Wnt5a knockout mice appear resistant to Bleomycin induced skin sclerosis[128].

Immunoinflammation
Innate responses
The potential role of the innate immune system in triggering the complex profibrotic cascade is of increasing interest. Type 1 IFNs are key innate mediators and are intimately linked with TLR-signaling (see Figure 2). TLR-3 is involved in downstream increases in inflammatory and profibrotic cytokines and chemokines such as IL-6 and IP10 (CXCL10), as well as increased responsiveness of fibroblasts to TGF-β[46]. Additionally, synthetic TLR3-ligand induces the expression of several ECM genes in fibroblasts and dermal fibrosis in mouse models[129].

Interferon-regulatory factor 5 (IRF5) is a transcription factor involved in TLR-signaling and activation of target IFN genes[130]. IRF5 has been coined a susceptibility factor to SSc and its potential role in pulmonary fibrosis has been identified[130].

Further implicating IFN in fibrosis is signal transducer and activator of transcription 4 (STAT4), which induces expression of type 1 IFNs, and STAT4 null mice exposed to bleomycin develop reduced fibrosis compared to controls[130]. STAT4 is also pivotal in pro-inflammatory cytokine production including TNF-α, IL-2 and IL-6; hence its role in an inflammatory model of fibrosis is potentially relevant to morphoea, where an inflammatory signature has been demonstrated in some[23].

NF-kappaB, the master regulator of innate immune signaling, is important in skin homeostasis and more recently a profibrotic role of the c-Rel subunit expression within keratinocytes has been suggested, with abnormal epidermal expression patterns in SSc skin compared to healthy controls[131].

Inflammasome activation and IL-1β production is also implicated in many animal models of fibrosis, and has a potential role in SSc[132][133] (see Figure 1 and 2). Indeed, NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome and IL-1β levels correlate with

mRSS and immunohistochemistry staining shows strong NLRP3 and IL-1β staining in the epidermis of SSc skin[133]. Similarly, ET-1 levels correlate with NLRP3 and mRSS, ET-1 receptors are increased in SSc[133-137], and external stimuli can induce ET-1 and concurrent TGF- β production by oral mucosal keratinocytes in oral submucous fibrosis[134].

Adaptive responses

A cytokine profile based conceptual model of the immunopathology of morphoea was recently proposed[138] and has been supported by further cytokine expression profiling.[139-143] An early active disease phase characterized by inflammation with a Th1 cytokine response (mediated by IL-2, TNF-α and IL-6) appears to be followed by ongoing inflammation and initiation of fibrosis driven by Th17 related IL-1, IL-17, IL-22 and TGF-β production. Subsequent progression to a final fibrotic and atrophic phase then occurs, predominated by Th2 cytokines (IL-4 and IL-13)[138] (see Figure 1 and 2).

Correspondingly, raised IL-2, IL-2 receptor and TNF-α levels are seen in early phase morphoea[15 139 144] and correlate with IL-4 and IL-6 levels, objective skin scores[138-140], anti-histone and anti-ssDNA antibodies[142]. Serum IL-1 and IL-6 levels (Th-17 inducers) are also elevated during early disease (<24 months), whilst levels of Th17 effectors (IL-17F and IL-22) become elevated later (24-48 months)[138 145]. IL-6, stimulated by IL-1, is required for wound healing and fibroblast activity, and is intimately involved in morphoea[146]. In response to injury, IL-1, via IL-6 and PDGF, promotes fibroblast proliferation, resultant transcription of type I, III and IV collagens[83 147] and CTGF expression[148]. IL-1 pathways can also activate fibroblasts in SSc [149]. Further, low IL-17C with high IL-17E and IL-22 increases fibroblast profibrotic responses which is further enhanced in the presence of IL-22 and TNF activated keratinocytes in both SSc and morphoea[150]. IL-17A also appears important, with levels decreasing in correlation with TGF-β and IL-22 in the setting of polymerised collagen treatment and associated normalisation of dermal architecture in morphoea skin[151].

TGF-β is recognized as a potential master regulator of wound healing and a driver of pathological fibrosis[135]. Increased levels of TGF-β and TGF-β receptor-I and II have been demonstrated in skin biopsies and sera of morphoea and SSc patients[138 152-157]. In addition, and perhaps highly relevant, is the key role of TGF-β in regulating normal embryonic and fetal growth and development, as well as postnatal growth of connective tissue. A number of MMPs and tissue inhibitor of metalloproteinases (TIMPs) are also deregulated by TGF-β expression[158]; promoting ECM production and limiting degradation. MMP-12 is over expressed in SSc and associated with extent of skin disease, disease duration and severity of pulmonary fibrosis[159 160]. Similarly, MMP-12 may be implicated in the antifibrotic affects of UVA1 phototherapy[161].

Finally in this cytokine profile based model of morphoea, Th2 related IL-4 and IL-13 appear to be are linked to the late fibrotic, as well as final atrophic and/or hyperpigmented phases of morphoea morphology. Regarding fibrosis, IL-4 and IL-13 up-regulate collagen synthesis, inhibit collagenase activity[143], with elevated IL-13 levels have been demonstrated in some morphoea patients in the late fibrotic stage[140]. In addition, IL-13 pathways may be interlinked with TGF-β and CCL2, and recent gene expression profiling of morphoea patients confirmed increased IL-13 and CCL2 activity[23].

The role of B-cells in morphoea is also well supported. As mentioned, a personal or family history of an associated autoimmune or rheumatologic diagnosis can occur in 9 to 46% of those with morphoea[2 5 7-9]. Accordingly, the systemic autoimmune nature of morphoea is

further recognised by a variety of autoantibodies[2 7 10 11], and an increased level of B-cell activating factor in the serum of affected patients further infers systemic autoimmunity[162]. Antinuclear antibodies (ANA) can occur in 18 to 68%[2 9 12-20]. Furthermore, B-cells are known to produce profibrotic cytokines such as IL-6 and TGF-β, promote a profibrotic Th2 response and regulatory B-cells (which inhibit Th1 and Th17) are decreased in SSc[163].

Mesenchyme and Fibroblasts
Myofibroblasts are the key effecter cell in fibrosis. Upon injury, fibroblasts migrate towards a wound and, under the influence of growth factors, differentiate into secretory myofibroblasts; central to repair during wound healing[115]. In wounds, the process of myofibroblast activation and population expansion are appropriately switched off via apoptosis or de-activation. In contrast, this physiological balance is deregulated in pathological fibrosis, including morphoea, and a pro-fibrotic environment rich in activating signals such as TGF-β, FGFs and CTGF inappropriately persists[115] (see Figure 1 and 2).

Studies support the role of fibroblast transdifferentiation in fibrotic skin disease, which expands resident fibroblast populations from many other differentiated cell lineages. Bone morphogenetic protein-2 (BMP-2) induced TNF-α, TGF-β Smad signaling, CTGF, FGF as well as developmental pathways (Wnt, Shh and Jagged-Notch) all potentially induce epithelial to myofibroblast transformation in keratinocytes, and are separately implicated in skin fibrosis[164-169]. Interestingly, and of potential relevance to Blaschkoid morphoea, is the increased keratinocyte expression of α-smooth muscle actin in patients with stiff skin syndrome (fibrillin-1 gene mutation) and the related lack of normal basal layer keratinocyte columnar organization[100 101]. In addition to transdifferentiation, the aberrant differentiation of circulating bone marrow-derived mesenchymal progenitors (fibrocytes) into fibroblasts and myofibroblasts is also described in SSc[170 171].

Mesenchymal patterning and location-specific gene expression
Fibroblasts show location specific gene expression, formally referred to as 'positional identity'. The master regulating genes of positional identity during development are the homeodomain genes of the HOX sub-family, along with their co-factors, TALE. HOX-genes encode transcriptional factors that determine the positional identity of fibroblasts along anterior-posterior and secondary axes[109 172-175]. Hence fibroblasts from different sources, although immunophenotypically very similar, display distinct and site-specific HOX and TALE signatures; for example, HOXA13 is expressed in distal fibroblasts and is required for normal toe, finger and foreskin development[172 173]. Importantly, site-specific HOX and TALE transcriptional patterns remain stable throughout life and hence epigenetic factors are at play[172 173].

As one may elucidate, such site specific gene signatures are not only responsible for determining position and patterning during development, but also play a pivotal role in subsequent downstream orchestration of site-specific mesenchymal cell differentiation and related pathway signaling; acting as micromanagers of adult cell differentiation[109 176]. Many patterning and developmental pathways, including Shh and Wnt are involved[177], and the resultant regional diversification, which can be traced back to specific axial positions, may suggest that fibroblasts at different sites should actually be considered as groups of distinctly differentiated cells[109 177-180]. Importantly, these many pathways which are

instrumental in developmental patterning, positional identity, regional-specific mesenchymal differentiation and overlying epidermal fate, are intricately linked to pathogenesis of fibrosis via site specific expression of factors including TGF-β, Wnt, FGFs, BMP, receptor kinase, phosphatase families and G-protein signaling[109][173] (see Figure 1). Hence somewhat unsurprisingly their pathogenic role in SSc specific skin and internal organ disease is documented[46][181], and although likely of relevance, currently there are no specific investigations into the role of these mechanisms in morphoea (see Figure 2).

POTENTIAL MOLECULAR MECHANISM OF MORPHOEA CLINICAL SUBSETS

Although there are clearly several shared aetiopathogenic mechanisms across the spectrum of morphoea, there must be underlying determinants of anatomical patterning and the variably sclerotic, atrophic and pigmented morphology observed clinically (see Figure 1). In some, this will likely reflect local susceptibility factors including regional genetic and/or epigenetic perturbation, as described above. Whilst in others it may suggest distinct pathogenic mechanisms. As alluded to, morphoea classically evolves through three clinical stages; active inflammation, followed by sclerosis and then dyspigmentation and/or atrophy. However, there is marked variation within this phenotypic spectrum, both between and within individual patients; for example, atrophoderma may present without clinically apparent preceding inflammation or sclerosis in some or all lesions. Epigenetics, perturbation of homeostatic signaling (eg. α-MSH/MRC1, positional identify or Wnt-signaling) and/or aberrant recruitment of antifibrotic pathways may be at play. Of relevance, FDH (an X-linked genodermatosis; porcupine homolog gene (PORCN) mutation) results in Blaschkoid distributed dermal atrophy and pigmentation. PORCN gene expression causes epidermally-derived palmotoleic acid induced Wnt-signaling and protein release. It has been suggested that this subsequently regulates underlying dermal development and could account for the Blaschkoid distribution of FDH[40]. Thus, beyond providing an example of a dermal Blaschkoid process, the pathogenesis of FDH may in fact be more closely related to morphoea than immediately appreciated.

IMPLICATIONS FOR THERAPY

With improved understanding of the molecular pathogenesis of morphoea, it is likely that more precisely targeted biologic therapies directed towards specific immunoinflammatory and connective tissue repair pathways will become increasingly available (see Table 1).

As discussed, the role of activated T-cells is described in the pathogenesis of morphoea and well understood in SSc and animal models of skin fibrosis[138][182][183]. Abatacept (recombinant IgG1 fusion protein to cytotoxic T-lymphocyte antigen 4 (CTLA4)), inhibits activated T-cells by binding to CD80 and CD86, thereby blocking interactions with CD28. Thus, abatacept has resulted in significant improvement in two cases of deep and extensive morphoea[184] and further cases of SSc[185][186].

Infliximab (chimeric monoclonal antibody to TNF-α) has induced remission in one case of generalised morphoea[187] and three cases of eosinophilic fasciitis[188-190]. As a Th1 cytokine linked to the early inflammatory phase of morphoea, one can elucidate how TNF-α inhibition could be a useful therapy. However, etanercept (TNF-α receptor fusion protein) has been linked to the subsequent development of disseminated plaque morphoea (at sites related and completely separate to injections) in a patient with psoriasis receiving therapy for 18 months[191]. Whether this was due to injection site related trauma and a subsequent

systemic response, or a trauma unrelated paradoxical immunological drug response, remains unclear.

Imatinib (tyrosine kinase inhibitor) via anti-TGF-β and PDGF effects, showed promising results in three cases of morphoea[192-194] (see Table 1). Whilst not yet used in morphoea, tocilizumab (humanized IL-6 receptor monoclonal antibody) has been used with some success in SSc[195-197]. In experimental SSc mouse models, PPAR (γ and α) agonist IVA337 can decrease ECM deposition and TGF-β related Smad-signaling[198]. And finally, PDE4 inhibition (Apremalast®) reduces and inhibits fibrosis in a mouse model of sclerotic skin disease, with amelioration of skin fibrosis in sclerodermoid GVHD[103].

Based on present understanding of pathogenesis, future targets for morphoea could include IL-1 (Anakinra; anti-IL1), IL-13, IL17E, TGF-β or Wnt-signaling pathway mediators, among others (see Table 1). Importantly, the potential for non-systemic routes of administration, such as topical preparations in optimized vehicles, long acting patches, or local intradermal or subcutaneous injection, may improve tolerability and increase therapeutic benefit to risk ratios.

CONCLUSIONS

The complexity of morphoea aetiopathogenesis is clear. Whilst some broadly involved immunoinflammatory and profibrotic signaling cascades are elucidated, an overlay of clinical heterogeneity means regional susceptibility mechanisms and distinct pathogenic determinants are likely implicated. In the age of genetic profiling and advanced molecular science, more precise characterisation of systemic and local genetic and immunopathologic factors underpinning the anatomical and morphologic variability in morphoea, may open the door to novel targeted therapeutic approaches.

REFERENCES

1. Jacobe H, Ahn C, Arnett FC, et al. Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort. Arthritis & rheumatology (Hoboken, NJ) 2014;**66**(11):3170-7.
2. Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Archives of dermatology 2009;**145**(5):545-50.
3. Brownell I, Soter NA, Franks AG, Jr. Familial linear scleroderma (en coup de sabre) responsive to antimalarials and narrowband ultraviolet B therapy. Dermatology online journal 2007;**13**(1):11.
4. Anderson PJ, Molony D, Haan E, et al. Familial Parry-Romberg disease. International journal of pediatric otorhinolaryngology 2005;**69**(5):705-8.
5. Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford, England) 2006;**45**(5):614-20.
6. Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. The Journal of rheumatology 1997;**24**(1):73-80.
7. Pequet MS, Holland KE, Zhao S, et al. Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients. The British journal of dermatology 2014;**170**(4):895-900.

8. Kim A, Marinkovich N, Vasquez R, et al. Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort. The Journal of rheumatology 2014;**41**(1):106-12.

9. Kreuter A, Wischnewski J, Terras S, et al. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. Journal of the American Academy of Dermatology 2012;**67**(6):1157-62.

10. Harrington CI, Dunsmore IR. An investigation into the incidence of auto-immune disorders in patients with localized morphoea. The British journal of dermatology 1989;**120**(5):645-8.

11. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis and rheumatism 2005;**52**(9):2873-81.

12. Falanga V, Medsger TA, Jr. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. Journal of the American Academy of Dermatology 1987;**17**(4):648-56.

13. Falanga V, Medsger TA, Jr., Reichlin M. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Archives of dermatology 1987;**123**(3):350-3.

14. Marzano AV, Menni S, Parodi A, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. European journal of dermatology : EJD 2003;**13**(2):171-6.

15. Uziel Y, Krafchik BR, Feldman B, et al. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 1994;**37**(6):898-901.

16. Rosenberg AM, Uziel Y, Krafchik BR, et al. Antinuclear antibodies in children with localized scleroderma. The Journal of rheumatology 1995;**22**(12):2337-43.

17. Ruffatti A, Peserico A, Glorioso S, et al. Anticentromere antibody in localized scleroderma. Journal of the American Academy of Dermatology 1986;**15**(4 Pt 1):637-42.

18. Takehara K, Moroi Y, Nakabayashi Y, et al. Antinuclear antibodies in localized scleroderma. Arthritis and rheumatism 1983;**26**(5):612-6.

19. Vancheeswaran R, Black CM, David J, et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis and rheumatism 1996;**39**(6):1041-9.

20. Dharamsi JW, Victor S, Aguwa N, et al. Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea. JAMA dermatology 2013;**149**(10):1159-65.

21. Pendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. The Journal of investigative dermatology 2012;**132**(5):1363-73.

22. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. The Journal of investigative dermatology 2010;**130**(3):694-705.

23. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PloS one 2008;**3**(7):e2696.

24. Sargent JL, Whitfield ML. Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert review of clinical immunology 2011;**7**(4):463-73.

25. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proceedings of the National Academy of Sciences of the United States of America 2003;**100**(21):12319-24.

26. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis and rheumatism 2006;**54**(6):1961-73.

27. Magee KE, Kelsey CE, Kurzinski KL, et al. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis research & therapy 2013;**15**(6):R188.

28. Jackson R. The lines of Blaschko: a review and reconsideration: Observations of the cause of certain unusual linear conditions of the skin. The British journal of dermatology 1976;**95**(4):349-60.

29. Bolognia JL, Orlow SJ, Glick SA. Lines of Blaschko. Journal of the American Academy of Dermatology 1994;**31**(2 Pt 1):157-90; quiz 90-2.

30. Hauser C, Skaria A, Harms M, et al. Morphoea following Blaschko's lines. The British journal of dermatology 1996;**134**(3):594-5.

31. Soma Y, Fujimoto M. Frontoparietal scleroderma (en coup de sabre) following Blaschko's lines. Journal of the American Academy of Dermatology 1998;**38**(2 Pt 2):366-8.

32. Soma Y, Kawakami T, Yamasaki E, et al. Linear scleroderma along Blaschko's lines in a patient with systematized morphea. Acta dermato-venereologica 2003;**83**(5):362-4.

33. McKenna DB, Benton EC. A tri-linear pattern of scleroderma 'en coup de sabre' following Blaschko's lines. Clinical and experimental dermatology 1999;**24**(6):467-8.

34. Itin PH, Schiller P. Double-lined frontoparietal scleroderma en coup de sabre. Dermatology (Basel, Switzerland) 1999;**199**(2):185-6.

35. Mukhopadhyay AK. Linear scleroderma following Blaschko's lines. Indian journal of dermatology, venereology and leprology 2005;**71**(6):421-2.

36. Asano Y, Ihn H, Tamaki K. An unusual manifestation of linear scleroderma 'en coup de sabre' on the vertex and frontoparietal regions. Clinical and experimental dermatology 2007;**32**(6):758-9.

37. Rai R, Handa S, Gupta S, et al. Bilateral en coup de sabre-a rare entity. Pediatric dermatology 2000;**17**(3):222-4.

38. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines. The British journal of dermatology 2008;**159**(1):175-81.

39. Jue MS, Kim MH, Ko JY, et al. Digital image processing for the acquisition of graphic similarity of the distributional patterns between cutaneous lesions of linear scleroderma and Blaschko's lines. The Journal of dermatology 2011;**38**(8):778-83.

40. Paller AS. Wnt signaling in focal dermal hypoplasia. Nature genetics 2007;**39**(7):820-1.

41. Morice-Picard F BF, Lepreux S, Labreze C, Lacombe D, Taieb A. Severe linear form of granuloma annulare along Blaschko's lines preceding the onset of a classical form of granuloma annulare in a child. British Journal of Dermatology 2007;**157**(5):1056-8.

42. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis and rheumatism 2006;**54**(7):2271-9.
43. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proceedings of the National Academy of Sciences of the United States of America 2002;**99**(6):3908-13.
44. G Salazar JH, M Wu, X Guo, X Zhuo, J Charles, O Distler, E Pachera, M Mayes, S Assassi. The global microrna profile of systemic sclerosis whole skin/dermal fibroblasts and the role of the XQ26.3 mirna cluster as a TGFB pathway positive feedback mechanism. Journal of Scleroderma and Related Disorders 2016;**1**(1):47-8.
45. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2010;**182**(2):220-9.
46. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nature reviews Rheumatology 2012;**8**(1):42-54.
47. Tanaka S, Suto A, Ikeda K, et al. Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor beta. Rheumatology (Oxford, England) 2013;**52**(11):1963-72.
48. Etoh M, Jinnin M, Makino K, et al. microRNA-7 down-regulation mediates excessive collagen expression in localized scleroderma. Archives of dermatological research 2013;**305**(1):9-15.
49. Makino K, Jinnin M, Hirano A, et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. Journal of immunology (Baltimore, Md : 1950) 2013;**190**(8):3905-15.
50. Makino T, Jinnin M, Etoh M, et al. Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients. European journal of dermatology : EJD 2014;**24**(4):470-6.
51. Prinz JC KZ, Weisenseel P, Poto L, Battyani Z, Ruzzicka T. Borrelia-associated early-onset morphea: a particular type of scleroderma in childhood and adolescence with high tire antinuclear antibodies? Results of a cohort analysis and presentation of three cases. Journal of the American Academy of Dermatology 2009;**60**(2):8.
52. Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. Journal of the American Academy of Dermatology 2011;**64**(2):231-42; quiz 43-4.
53. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology 2011;**64**(2):217-28; quiz 29-30.
54. Grabell D, Hsieh C, Andrew R, et al. The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the Morphea in Adults and Children cohort IV. Journal of the American Academy of Dermatology 2014;**71**(3):493-8.
55. Ahn JG, Kim YT, Lee CW. Trauma-induced isomorphic lesions in morphea--a brief case report. Journal of Korean medical science 1995;**10**(2):152-4.
56. Ciechomska M, Cant R, Finnigan J, et al. Role of toll-like receptors in systemic sclerosis. Expert reviews in molecular medicine 2013;**15**:e9.
57. Drago F, Rampini P, Lugani C, et al. Generalized morphoea after antitetanus vaccination. Clinical and experimental dermatology 1998;**23**(3):142.

58. Torrelo A, Suarez J, Colmenero I, et al. Deep morphea after vaccination in two young children. Pediatric dermatology 2006;**23**(5):484-7.
59. Benmously Mlika R, Kenani N, Badri T, et al. Morphea profunda in a young infant after hepatitis B vaccination. Journal of the American Academy of Dermatology 2010;**63**(6):1111-2.
60. Khaled A, Kharfi M, Zaouek A, et al. Postvaccination morphea profunda in a child. Pediatric dermatology 2012;**29**(4):525-7.
61. Matsumoto M, Yamamoto T. Pediatric generalized morphea that developed at a BCG vaccination site. Actas dermo-sifiliograficas 2015;**106**(2):150-2.
62. Morell A, Betlloch I, Sevila A, et al. Morphea-like reaction from vitamin K1. International journal of dermatology 1995;**34**(3):201-2.
63. Alonso-Llamazares J, Ahmed I. Vitamin K1-induced localized scleroderma (morphea) with linear deposition of IgA in the basement membrane zone. Journal of the American Academy of Dermatology 1998;**38**(2 Pt 2):322-4.
64. Ho J, Rothchild YH, Sengelmann R. Vitamin B12-associated localized scleroderma and its treatment. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al] 2004;**30**(9):1252-5.
65. Frances L, Leiva-Salinas M, Angelica MB, et al. Morphea as a sign of autoimmune syndrome induced by adjuvants (ASIA). European journal of dermatology : EJD 2014;**24**(3):377-8.
66. Akay BN, Sanli H, Heper AO. Postirradiation linear morphoea. Clinical and experimental dermatology 2010;**35**(4):e106-8.
67. Bleasel NR, Stapleton KM, Commens C, et al. Radiation-induced localized scleroderma in breast cancer patients. The Australasian journal of dermatology 1999;**40**(2):99-102.
68. Kumar S, Kolozsvary A, Kohl R, et al. Radiation-induced skin injury in the animal model of scleroderma: implications for post-radiotherapy fibrosis. Radiation oncology (London, England) 2008;**3**:40.
69. Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection? Lancet (London, England) 1985;**2**(8449):278.
70. Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. The American Journal of dermatopathology 1991;**13**(4):334-41.
71. Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. Journal of the American Academy of Dermatology 1995;**33**(4):617-20.
72. Goodlad JR, Davidson MM, Gordon P, et al. Morphoea and Borrelia burgdorferi: results from the Scottish Highlands in the context of the world literature. Molecular pathology : MP 2002;**55**(6):374-8.
73. Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. The British journal of dermatology 2000;**142**(4):636-44.
74. Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? The British journal of dermatology 2007;**157**(6):1189-98.
75. Prinz JC, Kutasi Z, Weisenseel P, et al. "Borrelia-associated early-onset morphea": a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. Journal of the American Academy of Dermatology 2009;**60**(2):248-55.

76. Kraigher O, Brenner S, Tur E. Anti-double-stranded DNA-positive unilateral generalized morphea in an adult, possibly exacerbated by ibuprofen. Archives of dermatology 2009;**145**(7):844-6.

77. Bouchard SM, Mohr MR, Pariser RJ. Taxane-induced morphea in a patient with CREST syndrome. Dermatology reports 2010;**2**(1):e9.

78. Kupfer I, Balguerie X, Courville P, et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. Journal of the American Academy of Dermatology 2003;**48**(2):279-81.

79. Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. Journal of the American Academy of Dermatology 2008;**59**(1):125-9.

80. Runger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. Journal of the American Academy of Dermatology 2012;**66**(3):e89-96.

81. Verdelli A, Antiga E, Bonciolini V, et al. Drug induction in connective tissue diseases. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2014;**149**(5):573-80.

82. Calistru AM, Baudrier T, Mota A, et al. Pseudoscleroderma possibly induced by intravesical instillation of mitomycin C. Journal of the American Academy of Dermatology 2010;**63**(6):e116-8.

83. Kondo S. The roles of keratinocyte-derived cytokines in the epidermis and their possible responses to UVA-irradiation. The journal of investigative dermatology Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research 1999;**4**(2):177-83.

84. Shephard P, Hinz B, Smola-Hess S, et al. Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes. Thrombosis and haemostasis 2004;**92**(2):262-74.

85. Ghaffari A, Kilani RT, Ghahary A. Keratinocyte-conditioned media regulate collagen expression in dermal fibroblasts. The Journal of investigative dermatology 2009;**129**(2):340-7.

86. Koskela A, Engstrom K, Hakelius M, et al. Regulation of fibroblast gene expression by keratinocytes in organotypic skin culture provides possible mechanisms for the antifibrotic effect of reepithelialization. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2010;**18**(5):452-9.

87. Aden N, Shiwen X, Aden D, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford, England) 2008;**47**(12):1754-60.

88. Nikitorowicz-Buniak J, Shiwen X, Denton CP, et al. Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9. The Journal of investigative dermatology 2014;**134**(11):2693-702.

89. McCoy SS RT, Tsou PS, Khanna D, Kahlenberg JM, Berthier CC. . Scleroderma keratinocytes promote fibroblast activation independent of TGFB. Arthritis Rheumatol 2015;**67**(Suppl 10):Abstract 3004.

90. Meyer M, Muller AK, Yang J, et al. The role of chronic inflammation in cutaneous fibrosis: fibroblast growth factor receptor deficiency in keratinocytes as an example. The journal of investigative dermatology Symposium proceedings / the

Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research 2011;**15**(1):48-52.

91. Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. The Journal of investigative dermatology 1996;**106**(4):729-33.

92. Yamamoto T, Sawada Y, Katayama I, et al. Nodular scleroderma: increased expression of connective tissue growth factor. Dermatology (Basel, Switzerland) 2005;**211**(3):218-23.

93. Muffley LA, Zhu KQ, Engrav LH, et al. Spatial and temporal localization of the melanocortin 1 receptor and its ligand alpha-melanocyte-stimulating hormone during cutaneous wound repair. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2011;**59**(3):278-88.

94. Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine reviews 2008;**29**(5):581-602.

95. Bohm M, Luger TA. Melanocortins in fibroblast biology--current update and future perspective for dermatology. Experimental dermatology 2004;**13 Suppl 4**:16-21.

96. Bohm M, Raghunath M, Sunderkotter C, et al. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. The Journal of biological chemistry 2004;**279**(8):6959-66.

97. Bohm M, Schiller M, Luger TA. Non-pigmentary actions of alpha-melanocyte-stimulating hormone--lessons from the cutaneous melanocortin system. Cellular and molecular biology (Noisy-le-Grand, France) 2006;**52**(2):61-8.

98. Garcia-Borron JC, Olivares C. Melanocortin 1 receptor and skin pathophysiology: beyond colour, much more than meets the eye. Experimental dermatology 2014;**23**(6):387-8.

99. Arnett FC, Tan FK, Uziel Y, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis and rheumatism 1999;**42**(12):2656-9.

100. Loeys BL, Gerber EE, Riegert-Johnson D, et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Science translational medicine 2010;**2**(23):23ra20.

101. Esterly NB, McKusick VA. Stiff skin syndrome. Pediatrics 1971;**47**(2):360-9.

102. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis and rheumatism 2001;**44**(4):893-901.

103. Maier C SG, Distler J, Beyer C. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of profibrotic cytokines from M2-macrophages. Journal of Scleroderma and Related Disorders 2016;**1**(1):28.

104. Niessen FB, Andriessen MP, Schalkwijk J, et al. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars. The Journal of pathology 2001;**194**(2):207-16.

105. Funayama E, Chodon T, Oyama A, et al. Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid. The Journal of investigative dermatology 2003;**121**(6):1326-31.

106. Bellemare J, Roberge CJ, Bergeron D, et al. Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars. The Journal of pathology 2005;**206**(1):1-8.

107. Mustoe TA, Gurjala A. The role of the epidermis and the mechanism of action of occlusive dressings in scarring. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2011;**19 Suppl 1**:s16-21.

108. Simon F, Bergeron D, Larochelle S, et al. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns : journal of the International Society for Burn Injuries 2012;**38**(3):421-7.

109. Chang HY, Chi JT, Dudoit S, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 2002;**99**(20):12877-82.

110. Akgedik R, Akgedik S, Karamanli H, et al. Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats. Inflammation 2012;**35**(5):1732-41.

111. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Annals of the rheumatic diseases 2012;**71**(5):785-9.

112. Aoyagi-Ikeda K, Maeno T, Matsui H, et al. Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-{beta}-Smad3 pathway. American journal of respiratory cell and molecular biology 2011;**45**(1):136-44.

113. Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis and rheumatism 2010;**62**(11):3477-87.

114. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and rheumatism 2011;**63**(5):1396-404.

115. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis research & therapy 2013;**15**(3):215.

116. Carthy JM, Garmaroudi FS, Luo Z, et al. Wnt3a induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a beta-catenin-dependent manner. PloS one 2011;**6**(5):e19809.

117. Chang W, Wei K, Jacobs SS, et al. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. The Journal of biological chemistry 2010;**285**(11):8196-206.

118. Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nature chemical biology 2010;**6**(11):829-36.

119. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis and rheumatism 2011;**63**(6):1707-17.

120. Hamburg-Shields E, DiNuoscio GJ, Mullin NK, et al. Sustained beta-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes. The Journal of pathology 2015;**235**(5):686-97.

121. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signalling: diseases and therapies. Nature reviews Genetics 2004;**5**(9):691-701.

122. Vlad A, Rohrs S, Klein-Hitpass L, et al. The first five years of the Wnt targetome. Cellular signalling 2008;**20**(5):795-802.

123. Konigshoff M, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal? American journal of respiratory cell and molecular biology 2010;**42**(1):21-31.

124. Bayle J, Fitch J, Jacobsen K, et al. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. The Journal of investigative dermatology 2008;**128**(4):871-81.

125. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. The American journal of pathology 2003;**162**(5):1495-502.

126. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. The Journal of clinical investigation 2009;**119**(4):772-87.

127. Lam AP, Flozak AS, Russell S, et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. American journal of respiratory cell and molecular biology 2011;**45**(5):915-22.

128. Cher C LN, Zhang Y, Huang J, Zerr K, Schambony A, Bayer Cm Schett Gm Distler J. Wnt/PCP-signaling as a B-catenin-independent pathway to promote fibroblast activation in SSc. Journal of Scleroderma and Related Disorders 2016;**1**(1):29.

129. Farina GA, York MR, Di Marzio M, et al. Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. The Journal of investigative dermatology 2010;**130**(11):2583-93.

130. Dumoitier N, Lofek S, Mouthon L. Pathophysiology of systemic sclerosis: state of the art in 2014. Presse medicale (Paris, France : 1983) 2014;**43**(10 Pt 2):e267-78.

131. Fullard N, Moles A, O'Reilly S, et al. The c-Rel subunit of NF-kappaB regulates epidermal homeostasis and promotes skin fibrosis in mice. The American journal of pathology 2013;**182**(6):2109-20.

132. Del Galdo F, Wermuth PJ, Addya S, et al. NFkappaB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Annals of the rheumatic diseases 2010;**69**(11):2024-33.

133. Martinez-Godinez MA, Cruz-Dominguez MP, Jara LJ, et al. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. The Israel Medical Association journal : IMAJ 2015;**17**(1):5-10.

134. Feng Y, Ling T. [Changes of cytokines secreted by human oral mucosa keratinocytes from oral submucous fibrosis in vitro]. Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology 2000;**18**(1):23-5.

135. Bhattacharyya S, Sargent JL, Du P, et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS one 2011;**6**(9):e23082.

136. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. The American journal of pathology 1997;**151**(3):831-41.

137. Shi-wen X, Kennedy L, Renzoni EA, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis and rheumatism 2007;**56**(12):4189-94.

138. Kurzinski K, Torok KS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011;**55**(2):157-64.

139. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Archives of dermatological research 1995;**287**(2):193-7.

140. Hasegawa M, Sato S, Nagaoka T, et al. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology (Basel, Switzerland) 2003;**207**(2):141-7.

141. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Archives of dermatology 1992;**128**(3):337-46.

142. Arkachaisri T, Fertig N, Pino S, et al. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. The Journal of rheumatology 2008;**35**(12):2439-44.

143. Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. The Journal of pharmacology and experimental therapeutics 2000;**292**(3):988-94.

144. Ihn H, Sato S, Fujimoto M, et al. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. The British journal of dermatology 1996;**134**(5):843-7.

145. Torok KS, Arkachaisri T, Medsger TA, Jr., et al. Th1 and Th17 cytokine signatures in early pediatric localized scleroderma. Arthritis and rheumatism 2006;**62**(Suppl 10).

146. Vasquez R, Sendejo C, Jacobe H. Morphea and other localized forms of scleroderma. Current opinion in rheumatology 2012;**24**(6):685-93.

147. Maas-Szabowski N, Fusenig NE. Interleukin-1-induced growth factor expression in postmitotic and resting fibroblasts. The Journal of investigative dermatology 1996;**107**(6):849-55.

148. Aden N, Nuttall A, Shiwen X, et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. The Journal of investigative dermatology 2010;**130**(9):2191-200.

149. Denton CP, Xu S, Black CM, et al. Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. The Journal of investigative dermatology 1997;**108**(3):269-74.

150. Lonati PA1 BN, Montanari E3, Fontao L4, Gabrielli A5, Vettori S6, Valentini G6, Laffitte E4, Kaya G4, Meroni PL7, Chizzolini C3. High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PloS one 2014;**19**(9).

151. L. F-CJO-AMLGJ-SCFL. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL- 22 and transforming growth factor-beta1 expression, and increases Foxp3-expressing cells in localized scleroderma. Clinical and experimental dermatology 2012;**37**(6):599-609.

152. Higley H, Persichitte K, Chu S, et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic

sclerosis, morphea, and Raynaud's phenomenon. Arthritis and rheumatism 1994;**37**(2):278-88.

153. Kubo M, Ihn H, Yamane K, et al. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. The Journal of rheumatology 2002;**29**(12):2558-64.

154. Hoyles RK, Khan K, Shiwen X, et al. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis and rheumatism 2008;**58**(4):1175-88.

155. Mori T, Kawara S, Shinozaki M, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. Journal of cellular physiology 1999;**181**(1):153-9.

156. Flanders KC. Smad3 as a mediator of the fibrotic response. International journal of experimental pathology 2004;**85**(2):47-64.

157. Shi-wen X, Pennington D, Holmes A, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Experimental cell research 2000;**259**(1):213-24.

158. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Current opinion in rheumatology 2001;**13**(6):505-11.

159. Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Annals of the rheumatic diseases 2012;**71**(6):1064-72.

160. Manetti M, Ibba-Manneschi L, Fatini C, et al. Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. The Journal of rheumatology 2010;**37**(9):1852-7.

161. Tewari A, Grys K, Kollet J, et al. Upregulation of MMP12 and its activity by UVA1 in human skin: potential implications for photoaging. The Journal of investigative dermatology 2014;**134**(10):2598-609.

162. Matsushita T, Hasegawa M, Matsushita Y, et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007;**16**(2):87-93.

163. Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmunity reviews 2016;**15**(2):155-61.

164. !!! INVALID CITATION !!! 18-20.

165. Tan X, Dagher H, Hutton CA, et al. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2010;**11**:21.

166. Reka AK, Kurapati H, Narala VR, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010;**9**(12):3221-32.

167. Yan C, Grimm WA, Garner WL, et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am J Pathol 2010;**176**(5):2247-58.

168. O'Kane D, Jackson MV, Kissenpfennig A, et al. SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitro. Exp Dermatol 2014;**23**(7):497-503.

169. Takahashi M, Akamatsu H, Yagami A, et al. Epithelial-mesenchymal transition of the eccrine glands is involved in skin fibrosis in morphea. J Dermatol 2013;**40**(9):720-5.

170. Gomer RH. Circulating progenitor cells and scleroderma. Current rheumatology reports 2008;**10**(3):183-8.

171. Kuwana M. [Roles of aberrant endothelial progenitor cells in pathogenesis of systemic sclerosis]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 2013;**36**(1):17-26.

172. Rinn JL, Wang JK, Allen N, et al. A dermal HOX transcriptional program regulates site-specific epidermal fate. Genes & development 2008;**22**(3):303-7.

173. Rinn JL, Wang JK, Liu H, et al. A systems biology approach to anatomic diversity of skin. The Journal of investigative dermatology 2008;**128**(4):776-82.

174. Rinn JL, Bondre C, Gladstone HB, et al. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS genetics 2006;**2**(7):e119.

175. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS biology 2004;**2**(2):E7.

176. Picchi J, Trombi L, Spugnesi L, et al. HOX and TALE signatures specify human stromal stem cell populations from different sources. Journal of cellular physiology 2013;**228**(4):879-89.

177. Akiyama H, Stadler HS, Martin JF, et al. Misexpression of Sox9 in mouse limb bud mesenchyme induces polydactyly and rescues hypodactyly mice. Matrix Biol 2007;**26**(4):224-33.

178. Ackema KB, Charite J. Mesenchymal stem cells from different organs are characterized by distinct topographic Hox codes. Stem cells and development 2008;**17**(5):979-91.

179. Nakashima K, de Crombrugghe B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet 2003;**19**(8):458-66.

180. Zhao Q, Behringer RR, de Crombrugghe B. Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat Genet 1996;**13**(3):275-83.

181. Denton CP, Ong VH. Targeted therapies for systemic sclerosis. Nature reviews Rheumatology 2013;**9**(8):451-64.

182. Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Annals of the rheumatic diseases 2005;**64**(8):1233-5.

183. Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clinical immunology (Orlando, Fla) 2011;**139**(3):249-57.

184. Stausbol-Gron B, Olesen AB, Deleuran B, et al. Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases. Acta dermato-venereologica 2011;**91**(6):686-8.

185. de Paoli FV, Nielsen BD, Rasmussen F, et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scandinavian journal of rheumatology 2014;**43**(4):342-5.

186. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Annals of the rheumatic diseases 2013;**72**(7):1217-20.

187. Diab M, Coloe JR, Magro C, et al. Treatment of recalcitrant generalized morphea with infliximab. Archives of dermatology 2010;**146**(6):601-4.

188. Tzaribachev N, Holzer U, Schedel J, et al. Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology (Oxford, England) 2008;**47**(6):930-2.

189. Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford, England) 2010;**49**(6):1184-8.

190. Poliak N, Orange JS, Pawel BR, et al. Eosinophilic fasciitis mimicking angioedema and treatment response to infliximab in a pediatric patient. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2011;**106**(5):444-5.

191. Stewart FA, Gavino AC, Elewski BE. New side effect of TNF-alpha inhibitors: morphea. Skinmed 2013;**11**(1):59-60.

192. Coelho-Macias V, Mendes-Bastos P, Assis-Pacheco F, et al. Imatinib: a novel treatment approach for generalized morphea. International journal of dermatology 2014;**53**(10):1299-302.

193. Inamo Y, Ochiai T. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate. Pediatric dermatology 2013;**30**(6):e191-3.

194. Moinzadeh P, Krieg T, Hunzelmann N. Imatinib treatment of generalized localized scleroderma (morphea). Journal of the American Academy of Dermatology 2010;**63**(5):e102-4.

195. Frech TM, Hudson M. Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature. Clinical and experimental rheumatology 2015;**33**(4 Suppl 91):S179-81.

196. Fernandes das Neves M, Oliveira S, Amaral MC, et al. Treatment of systemic sclerosis with tocilizumab. Rheumatology (Oxford, England) 2015;**54**(2):371-2.

197. Shima Y, Hosen N, Hirano T, et al. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modern rheumatology / the Japan Rheumatism Association 2015;**25**(1):134-7.

198. Ruzehaji N FC, Ponsoyer M et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Journal of Scleroderma and Related Disorders 2016;**1**(1):31-2.

Table 1. Selected potential key molecular pathogenic mechanisms in morphoea and related future treatment targets.

Mechanism / evidence of profibrotic action(s)		Target Therapies (experimental / available)
EPIDERMAL / KERATINOCYTE SIGNALLING		
Key examples; IL1, IL6, TNF-α, PDGF, FGF-receptors, CCL2, ET-1, Fibrillin-1, Fli-1, morphogenic signalling pathways		
αMSH / MCR1	Homeostatic pathway which modulates pro and anti-inflammatory cytokines to antagonize TGF-β induced skin fibrosis	- Afamelanotide (αMSH analogue)
S100A9	Stimulates fibroblast proliferation and CTGF via TLR4 signalling	
Keratinocyte FGF-receptors	Receptor loss leads to transepidermal water loss with IL-1, S100A8 and S100A9 production and resultant profibrotic response	
Fibrillin-1	ECM microfibrillar component overexpressed in some SSc populations, antibodies demonstrated in morphoea and mutation responsible for stiff skin syndrome	
Fli-1	Transcription factor; down-regulation induces SSc-like phenotype and enhances skin fibrosis via IL-1, IL-6 and IL-8 over-expression	
Wnt-signalling	Stimulates enhanced fibroblast proliferation, myofibroblast differentiation, collagen and ECM expression and CTGF. Inhibited by PPAR-γ receptor agonists. Inhibits epidermal responsiveness to FGF-receptors.	- IVA337 (PPAR (γ and α) agonist)
INNATE IMMUNITY		
TLR3	↑IL-6 ↑IP10 Heightened fibroblast responsiveness to TGF-β	- Tocilizumab (anti IL-6)
STAT4	↑ proinflammatory / profibrotic cytokines; TNF-α, IL-2, IL-6 ↑Type-1 IFNs, leading to increased fibrosis	- Lisofylline (blocks STAT-4 signalling)
NF-κB	Skin homeostatic pathway, profibrotic c-Rel subunit abnormally expressed in SSc keratinocytes	
IL-1 / NLRP3 inflammasome	Levels correlate with mRSS	- Anakinra (anti IL-1)
ADAPTIVE RESPONSES		
Early active inflammatory phase		
Th2 cytokines:		
IL-2, TNF-α, IL-6	Increased levels in early (<24 months) morphoea, correlate with skin scores	- Infliximab (anti-TNFα
Amplified inflammation and initiation of fibrosis		
Th17 cytokines:		
IL-1, IL-17, IL-22	Increased levels later (24-48 months) IL-1 promotes fibroblast proliferation, collagen production and CTGF expression	- Anakinra (anti IL-1) - Secukinumab / Ixekizumab (anti-IL-17A), Brodalumab (anti IL-17 receptor A), IL-17E or F antibodies
TGF-β	Potential master regulator of pathological fibrosis Increased levels in skin and serum	- Fresolimumab (anti TGF- β) - Pirfenidone gel (anti TGF- β)

	Up-regulates MMPs eg. MMP12 over-expressed in SSc
Final fibrotic and atrophic phase	
Th2 cytokines:	
IL-4, IL-13	Up-regulate collagen synthesis and inhibit collagenase activity ↑IL-13 levels and activity in morphoea IL-4 levels correlate with early inflammatory phase cytokines and skin scores
MESENCHYME AND FIRBOBLASTS	
Fibrocyte to myofibroblast trans-differentiation	Aberrant differentiation of mesenchymal progenitors described in SSc
Epithelial to myofibroblast trans-differentiation	Induced by cytokines and signalling involved in morphoea related fibrosis; TNF-α, TGF-β, CTGF, FGF2, Wnt, Shh and Jagged-notched. Demonstrated in stiff skin syndrome
Location specific mesenchymal gene expression and patterning	Determined by pathways and molecular mechanisms intricately linked to pathological fibrosis; TGF-β, Wnt, FGFs and others.

CLINICAL VARIABILITY

ANATOMICAL DISTRIBUTION

■ **Limited**
Plaques affecting
≤2 anatomical
sites

- Plaque: round/oval, >1cm
- Guttate: round/oval, <1cm
- Keloidal / Nodular
- Disseminated plaque: isomorphic / nonisomorphic

■ **Generalized**
Plaques affecting
≥3 anatomical
sites

Pansclerotic: circumferential, majority of body surface area

■ **Blaschkoid**
Follows
Blaschlo's
lines = linear
morphoea

- Head/neck: En coup de sabre / Progressive hemifacial atrophy
- Trunk
- Limb(s)

■ **Mixed** ≥2 distributions: eg. limited plaque and Blaschkoid

MORPHOLOGY

■ **Inflammatory**
– erythematous
– lilac ring
– bruise-like

■ **Sclerotic**

■ **Dyspigmented**
– hypopigmented
– hyperpigmented

■ **Atrophic**
– Dermal = shiny, visible vessels, 'cliff top'
– Subcutaneous = concave

DEPTH OF TISSUE INVOLVEMENT

■ **Dermal**

■ **Deep dermal / subcutis**
– May be nodular

■ **Fascia**
– Peau d'orange, guttering, 'groove sign'

■ **Muscle**
– Limb asymmetry

■ **Bone**
– Limb asymmetry

UNDERLYING MECHANISMS

REGIONAL DIVERSIFICATION

■ **Regional genetic / epigenetic susceptibity mechanisms**
– Blaschkoid mutations:
 • Epidermal signalling (eg. Wnt, PORCN gene)
 • Epithelial-mesenchymal transdifferentiation
– Keratinoyctes
 • eg S100A9, Fibrillin1, Fli1, innate pathways
– Mesenchymal patterning and location specific gene expression:
 • Positional identity
 • Site specific expression (eg. TGFβ, FGF)

■ **Location specific triggers**
 • eg friction: (isomorphic disseminated plaque morphoea), radiation field morphoea

IMMUNOINFLAMMATORY AND PROFIBROTIC MECHANISMS

■ **Innate**
– IFN, TLR, STAT4, NFκB, IL1

■ **Adaptive**
– IL2, TNFα, IL4, IL6, IL1, TGFβ, IL17, IL13, CCL2

■ **Connective tissue**
– FGF, CTGF, MMPs, TIMPs

■ **Developmental and homeostatic**
– Wnt, Jagged-Notch, Shh
– αMSH
– Aberrant antifibrotic mechanisms

■ **Inflammatory versus profibrotic genetic signatures**

SUSCEPTIBILITY MECHANISMS

GENETICS:
- HLA subtypes
- Mosaicism
- Family history
- Shared genetic loci; autoimmunity
- Intrinsic subsets; morphoea = inflammatory

+

EXTERNAL STIMULI

EPIGENETICS:
- Deregulated histone acetylation and DNA methylation
- micro RNAs eg. ↓miR-7, miR-196a

TRIGGERS:

EPIDERMIS:

↓FGF receptors 1 & 2

KERATINOCYTE PRODUCED:
- Fibrillin 1
- ∝MSH (↓)
- S100A8/A9
- ET1
- Fli 1 (↓)

SIGNALLING PATHWAYS
- Jagged - Notch
- Shh
- Wnt — Wnt5a
  - βCatenin — ↓PPARγ
  - ↓Kφ FGFR
  - ↑CTGF, TGFβ

EPIDERMAL – DERMAL SIGNALLING

DERMIS:

INNATE RESPONSES
- TLR signalling
- Interferons (Type 1, IRF5)
- STAT 4
- NFκβ
- NLRP 3 inflammasome IL1β

+

ADAPTIVE RESPONSES

EARLY ACTIVE PHASE:
Inflammation
IL2, TNF∝, IL6, IL1
EARLY FIBROSIS:
Inflammation and fibrosis
IL1, IL17E, IL22, TGFβ
LATE FIBROSIS/ATROPHY:
IL4, IL13

+

DEREGULATED PRO & ANTIFIBROTIC MECHANISMS
- PDGF
- CTGF
- TGFβ receptors
- ET1 receptors
- MMPs/TIMPs
- ∝MSH/MRC1
- FGF
- Periostin
- COMP
- Transdifferentiation
- ↑secretory fibroblasts

Figure 1. Linking clinical morphoea variability (anatomical, morphology and depth of tissue involvement), to possible underlying genetic and molecular mechanisms. Specifically, anatomical distributions may be explained by certain factors of regional diversification, whilst variations in morphology and depth of tissue involvement may be determined by differing immunoinflammatory and pro / anti-fibrotic pathways.

Figure 2. Proposed morphoea pathogenesis; underlying susceptibility mechanisms plus epigenetic and environmental factors combine to trigger a cascade of epidermal (keratinocyte) and dermal (fibroblast) innate, adaptive, fibrotic molecular mechanisms and signaling pathways, culminating in fibrosis.

α-MSH = α-melanocyte stimulating hormone , ET1 = endothelin 1; Fli1 = , Shh = Sonic hedgehog, Wnt = , PPAR = ,Kϕ FGFR = keratinocyte fibroblast growth factor receptors , CTGF = connective tissue growth factor, TGF-β = transforming growth factor , TLR = toll-like receptor, IRF5 = , STAT4 = , NLRP3 = , IL = interleukin, TNFα = tumour necrosis factor, PDFG = platelet derived growth factor, MMPs = matrix metalloproteins, TIMPs = tissue inhibitors of metalloproteinases, FGF = fibroblast growth factor, COMP = cartilage oligomeric matrix protein.